1-20 of 32
Timothy A. Yap
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression

Chuandong Geng, Man-Chao Zhang, Ganiraju C. Manyam, Jody V. Vykoukal, Johannes F. Fahrmann, Shan Peng, Cheng Wu, Sanghee Park, Shakuntala Kondraganti, Daoqi Wang, Brian D. Robinson, Massimo Loda, Christopher E. Barbieri, Timothy A. Yap, Paul G. Corn, Samir Hanash, Bradley M. Broom, Patrick G. Pilié, Timothy C. Thompson
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF15.
https://doi.org/10.1158/1078-0432.CCR-23-1439
Published: 14 September 2023
View article titled, SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Open the PDF for SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression in another window
Includes: Supplementary data
Journal Articles

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers

Timothy P. DiPeri, Kurt W. Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q. Rizvi, Xiaofeng Zheng, Bailiang Wang, Bryce P. Kirby, Kathleen Kong, Michael Kahle, Timothy A. Yap, Ecaterina E. Dumbrava, Jaffer A. Ajani, Siqing Fu, Khandan Keyomarsi, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF14.
https://doi.org/10.1158/1078-0432.CCR-23-0103
Published: 16 June 2023
View article titled, Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
Open the PDF for Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers in another window
Includes: Supplementary data
Journal Articles

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Roberto Carmagnani Pestana, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha-Paul, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour, Ravin Ratan, Vinod Ravi, Robert S. Benjamin, Alexander J. Lazar, Wei-Lien Wang, Najat Daw, Jonathan B. Gill, Douglas J. Harrison, Valerae O. Lewis, Christina L. Roland, Shreyaskumar R. Patel, J. Andrew Livingston, Neeta Somaiah, Joseph A. Ludwig, Anthony P. Conley, Nelson Hamerschlak, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (9): 1708–1718.
https://doi.org/10.1158/1078-0432.CCR-22-3629
Published: 01 May 2023
View article titled, Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
Open the PDF for Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101) in another window
Includes: Supplementary data
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View article titled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance

Timothy A. Yap, Patricia M. LoRusso, Deborah J. Wong, Siwen Hu-Lieskovan, Kyriakos P. Papadopoulos, Josefin-Beate Holz, Urszula Grabowska, Cristian Gradinaru, Kin-Mei Leung, Sylwia Marshall, Claire S. Reader, Roslin Russell, Richard C.A. Sainson, Claire J. Seal, Christopher J. Shepherd, Fiona Germaschewski, Daniel Gliddon, Omer Stern, Lesley Young, Neil Brewis, Louis Kayitalire, Michelle Morrow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (5): 888–898.
https://doi.org/10.1158/1078-0432.CCR-22-1449
Published: 01 March 2023
View article titled, A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
Open the PDF for A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance in another window
Includes: Supplementary data
Journal Articles

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Justin T. Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu, Sarina Piha-Paul, Timothy A. Yap, Daniel Karp, Jordi Rodon, Andy Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Joseph Ludwig, Cynthia Herzog, Ravin Ratan, Neeta Somaiah, Anthony Conley, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 401–409.
https://doi.org/10.1158/1078-0432.CCR-22-2509
Published: 17 January 2023
View article titled, Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)
Open the PDF for Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102) in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3695–3708.
https://doi.org/10.1158/1078-0432.CCR-21-4256
Published: 01 September 2022
View article titled, First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Open the PDF for First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response in another window
Includes: Supplementary data
Journal Articles

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Timothy A. Yap, Maria Vieito, Capucine Baldini, Juan Manuel Sepúlveda-Sánchez, Shunsuke Kondo, Matteo Simonelli, Rasha Cosman, Andre van der Westhuizen, Victoria Atkinson, Antoine F. Carpentier, Mario Löhr, Rebecca Redman, Warren Mason, Andres Cervantes, Emilie Le Rhun, Sebastian Ochsenreither, Louise Warren, Yumin Zhao, Sophie Callies, Shawn T. Estrem, Michael Man, Leena Gandhi, Emin Avsar, Davide Melisi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6666–6676.
https://doi.org/10.1158/1078-0432.CCR-21-1504
Published: 15 December 2021
View article titled, First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Open the PDF for First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer in another window
Journal Articles

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Timothy A. Yap, Matthew G. Krebs, Sophie Postel-Vinay, Anthony El-Khouiery, Jean-Charles Soria, Juanita Lopez, Alienor Berges, S.Y. Amy Cheung, Itziar Irurzun-Arana, Andrew Goldwin, Brunella Felicetti, Gemma N. Jones, Alan Lau, Paul Frewer, Andrew J. Pierce, Glen Clack, Christine Stephens, Simon A. Smith, Emma Dean, Simon J. Hollingsworth
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5213–5224.
https://doi.org/10.1158/1078-0432.CCR-21-1032
Published: 01 October 2021
View article titled, Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study in another window
Journal Articles

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

Zhe Tang, Patrick G. Pilié, Chuandong Geng, Ganiraju C. Manyam, Guang Yang, Sanghee Park, Daoqi Wang, Shan Peng, Cheng Wu, Guang Peng, Timothy A. Yap, Paul G. Corn, Bradley M. Broom, Timothy C. Thompson
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4898–4909.
https://doi.org/10.1158/1078-0432.CCR-21-1010
Published: 01 September 2021
View article titled, ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
Open the PDF for ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer in another window
Journal Articles

A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies

Aparna Hegde, Priyamvada Jayaprakash, Coline A. Couillault, Sarina Piha-Paul, Daniel Karp, Jordi Rodon, Shubham Pant, Siqing Fu, Ecaterina E. Dumbrava, Timothy A. Yap, Vivek Subbiah, Priya Bhosale, Cristian Coarfa, Jack P. Higgins, Eric T. Williams, Thomas F. Wilson, JoAnn Lim, Funda Meric-Bernstam, Elizabeth Sumner, Hira Zain, Di Nguyen, Ly M. Nguyen, Kimal Rajapakshe, Michael A. Curran, David S. Hong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3050–3060.
https://doi.org/10.1158/1078-0432.CCR-20-4118
Published: 01 June 2021
View article titled, A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
Open the PDF for A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung, Maria J. de Miguel, Yung-Jue Bang, Chia-Chi Lin, Wu-Chou Su, Antoine Italiano, Kay Hoong Chow, Anna M. Szpurka, Danni Yu, Yumin Zhao, Michelle Carlsen, Shelly Schmidt, Burkhard Vangerow, Leena Gandhi, Xiaojian Xu, Johanna Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1267–1277.
https://doi.org/10.1158/1078-0432.CCR-20-2821
Published: 01 March 2021
View article titled, Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Open the PDF for Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial in another window
Includes: Supplementary data
Journal Articles

Abstract IA14: Targeting the DNA damage response in head and neck cancers

Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_2): IA14.
https://doi.org/10.1158/1557-3265.AACRAHNS19-IA14
Published: 15 June 2020
View article titled, Abstract IA14: Targeting the DNA damage response in head and neck cancers
Journal Articles

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

Timothy A. Yap, Jane N. Winter, Lisa Giulino-Roth, Jemma Longley, Juanita Lopez, Jean-Marie Michot, John P. Leonard, Vincent Ribrag, Michael T. McCabe, Caretha L. Creasy, Melissa Stern, Teodora Pene Dumitrescu, Xiaowei Wang, Steve Frey, Jennifer Carver, Thierry Horner, Choon Oh, Ahmed Khaled, Arindam Dhar, Peter W.M. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7331–7339.
https://doi.org/10.1158/1078-0432.CCR-18-4121
Published: 13 December 2019
View article titled, Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors
Open the PDF for Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors in another window
Includes: Supplementary data
Journal Articles

PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, Mark J. O'Connor, Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 3759–3771.
https://doi.org/10.1158/1078-0432.CCR-18-0968
Published: 01 July 2019
View article titled, PARP Inhibitors: Extending Benefit Beyond <em>BRCA</em>-Mutant Cancers
Open the PDF for PARP Inhibitors: Extending Benefit Beyond <em>BRCA</em>-Mutant Cancers in another window
Journal Articles

Precision Oncology Decision Support: Current Approaches and Strategies for the Future

Katherine C. Kurnit, Ecaterina E. Ileana Dumbrava, Beate Litzenburger, Yekaterina B. Khotskaya, Amber M. Johnson, Timothy A. Yap, Jordi Rodon, Jia Zeng, Md Abu Shufean, Ann M. Bailey, Nora S. Sánchez, Vijaykumar Holla, John Mendelsohn, Kenna Mills Shaw, Elmer V. Bernstam, Gordon B. Mills, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2719–2731.
https://doi.org/10.1158/1078-0432.CCR-17-2494
Published: 14 June 2018
View article titled, Precision Oncology Decision Support: Current Approaches and Strategies for the Future
Open the PDF for Precision Oncology Decision Support: Current Approaches and Strategies for the Future in another window
Includes: Supplementary data
Journal Articles

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

Kurt W. Evans, Erkan Yuca, Argun Akcakanat, Stephen M. Scott, Natalia Paez Arango, Xiaofeng Zheng, Ken Chen, Coya Tapia, Emily Tarco, Agda K. Eterovic, Dalliah M. Black, Jennifer K. Litton, Timothy A. Yap, Debu Tripathy, Gordon B. Mills, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (21): 6468–6477.
https://doi.org/10.1158/1078-0432.CCR-17-0615
Published: 31 October 2017
View article titled, A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors
Open the PDF for A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors in another window
Includes: Supplementary data
Journal Articles

Combining Molecularly Targeted Agents: Is More Always Better?

Raghav Sundar, Nicola Valeri, Kevin J. Harrington, Timothy A. Yap
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1123–1125.
https://doi.org/10.1158/1078-0432.CCR-16-2399
Published: 28 February 2017
View article titled, Combining Molecularly Targeted Agents: Is More Always Better?
Open the PDF for Combining Molecularly Targeted Agents: Is More Always Better? in another window
Journal Articles

Abstract IA10: Targeting the DNA damage response in cancer: Progress in the clinic

Timothy A. Yap
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1_Supplement): IA10.
https://doi.org/10.1158/1557-3265.PMCCAVULN16-IA10
Published: 02 January 2017
View article titled, Abstract IA10: Targeting the DNA damage response in cancer: Progress in the clinic
Journal Articles

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

Jean Sebastien Frenel, Suzanne Carreira, Jane Goodall, Desam Roda, Raquel Perez-Lopez, Nina Tunariu, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Daniel Nava-Rodrigues, Alan Smith, Christophe Leux, Isaac Garcia-Murillas, Roberta Ferraldeschi, David Lorente, Joaquin Mateo, Michael Ong, Timothy A. Yap, Udai Banerji, Delila Gasi Tandefelt, Nick Turner, Gerhardt Attard, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4586–4596.
https://doi.org/10.1158/1078-0432.CCR-15-0584
Published: 14 October 2015
View article titled, Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Open the PDF for Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration in another window
Includes: Supplementary data